9 th Annual Symposium of the European LeukemiaNet. 13 th Annual Symposium of the German Competence Network Acute and chronic Leukemias.

Transcription

1 9 th Annual Symposium of the European LeukemiaNet 13 th Annual Symposium of the German Competence Network Acute and chronic Leukemias Program January 31 - February 1, 2012

2 CML (WP4), Registry (WP17) h Room Arnold Schönberg 1. EURO-SKI. Start meeting (60 min). F. Mahon, S. Saußele 2. Concise summaries of upcoming clinical trials from different study groups (60 min) F. Guilhot H. Hjorth-Hansen A. Hochhaus G. Rosti 3. Next WP4 meeting 4. Other topics

3 CLL (WP7) / ERIC Tuesday, February 31, h Room Gustav Mahler I Eric Board E. Montserrat (President), E. Kimby (Vice-president) P. Ghia, C. Moreno, S. Pospisilova Executive Committee Report E. Kimby, E. Montserrat Membership update ERIC at EHA 2012 preview Projects for 2012 P. Ghia Another step beyond: 8-colour MRD A. Rawstron p53 strategy and related projects S. Stilgenbauer CLL clinical form E. Kimby, C. Moreno CLL accreditation in Europe: a preliminary discussion S. Pospisilova K. Stamatopoulos Any other issues

4 MDS (WP8) h Room Gustav Mahler II Chairs: P. Fenaux, T. de Witte General issues Future of ELN MDS WP8 / EHA MDS working group T. de Witte, P. Fenaux, U. Platzbecker Report activities WP8 for ELN Newsletter All (see ELN Informationletter N o 8) Cooperation with Pharma All Future meetings All Iron substudy M. MacKenzie, T. de Witte (L. de Swart) EPO - studies A. Smith (E. Hellström-Lindberg) Diabetis Mellitus A. Symeonidis Cytopenias R. Itzykson, P. Fenaux Quality of Life R. Stauder Cytology review M. MacKenzie Translational research / biobanking: relationship with EUMDS-Registry activities GO MDS - application 7 th Framework program, second stage Platform for international studies, progress Flow cytometry on MDS, report Pavia meeting Therapeutic guidelines Progress of the ongoing studies of EUMDS Registry J. Jansen (E. Hellström-Lindberg) T. de Witte P. Fenaux, M. Mittelman, U. Platzbecker A. van de Loosdrecht L. Malcovati, M. Cazzola T. de Witte (E. Hellström-Lindberg)

5 Assembly European LeukemiaNet h Room Arnold Schönberg Inclusion of new participants Final Finance report EC ELN Foundation, progress report R. Hehlmann S. Saußele R. Hehlmann, N. Steidl Miscellaneous (e.g. perspective of sponsoring concept)

6 AML (WP5), Registry (WP17) h Room Arnold Schönberg 1. Introduction G. Ossenkoppele 2. Platform facilitating meta-analyses R. Schlenk 3. A model of interconnected clinical trials R. Schlenk 4. New data from the Swedish population based registry G. Juliusson 5. Update APL registry E. Lengfelder 6. AML German intergroup study M. Pfirrmann 7. New trial design in AML R. Hills 8. Update ELN/EBMT allosct in elderly AML D. Niederwieser 9. Further Business All

7 EWALL (WP6) h Room Gustav Mahler I Burkitt Leukemia / Lymphoma 1. Update of the German B-NHL Protokoll 2002 (confirmed) N. Gökbuget 2. Update of Italian Experience in Burkitt Lymphoma/ Leukemia (confirmed) 3. Results of the B-NHL protocol in PMBL +/- BL as compared to other approaches within the PLRG 4. Final results of the Spanish PETHEMA group in BLL, HIV + and negative patients (confirmed) R. Bassan J. Walewski J. Ribera Ph + ALL 5. Ph-like ALL, a unique subtype of BCR-ABL negative high-risk B-ALL (confirmed) G. Martinelli 6. Novel front line therapies in Ph+ ALL (t.b.c.) P. Rousselot 7. How much Imatinib and chemotherapy is required before SCT in patients with Ph+ ALL. The PETHEMA experience (confirmed) J. Ribera 8. Post SCT Strategies and Salvage approaches in Ph+ ALL (confirmed) O. Ottmann

8 Joint Meeting of Cytogenetics (WP11) and Gene profiling (WP13) h Room Gustav Mahler II Comprehensive molecular profiling of T-ALL Whole-genome sequencing in CLL New Cytogenetic risk score in MDS V. Grossmann J. Hernandez D. Haase

9 Cytogenetics (WP11) h Room Gustav Mahler II Report of the activities in 2011 Clinical impact of CD34+ FISH of peripheral blood cells Monosomal karyotype vs complex karyotype in AML The cytogenetic nomenclature - ambition and reality F. Braulke C. Haferlach H. Rieder Current sesearch projects Call for rare abnormalities in MDS J. Schanz Upcoming activities in 2012 WP meetings Workshops Collection of new recurring and rare chromosome aberrations Joint research activities - Calls for Cooperation

10 Gene profiling (WP13) h Room Gustav Mahler III Leukemia Gene Atlas Version 2: analysis functions and data sets SF3B1 and NOTCH1 mutations in CLL Experiences with amplicon NGS of mutation 'hotspots' in pediatric leukemias Status update on ELN-wide NGS working groups: IRON Phase II M. Dugas S. Chiaretti T. te Kronnie A. Kohlmann Upcoming activities in 2012 Joint research activities - Calls for Cooperation

11 CMPD (WP9) h Room Arnold Schönberg

12 Diagnostics (WP10) h Room Gustav Mahler I Update on morphology, new cells and München workshop Update on flow cytometry and minimal residual disease Roundtable about accreditation in flow cytometry

13 Minimal residual disease (WP12) h Room Gustav Mahler II Introduction D. Grimwade MRD detection in Core Binding Factor AML P. Paschka, H. Dombret Update on BCR-ABL standardization M.C. Müller Update on the MPN&MPNr-EuroNet guidelines and reference materials for the analysis of JAK2-V617F N. Pallisgaard JAK2-V617F Q-PCR study final results D. Grimwade Final discussion

14 Stem cell transplantation (WP14) h Room Gustav Mahler III Update on the projects of WP 14 HCT vs CT randomized study in elderly patients with AML new projects European Recommendations for the treatment of GvHD discussion

15 Scientific Symposium Wednesday, February 1, h Room Arnold Schönberg Chair: R. Hehlmann, D. Hoelzer Review of the evidence that BCR-ABL causes leukemia Is polycythemia curable? N. Heisterkamp R. Silver Frequent pathway mutations of splicing machinery in myelodysplasia D. Nowak Perspectives of clinical trials and related publications in the field of leukemia 2012 Cytogenetic aberrations versus mutations in AML C. Schiffer C. Haferlach